Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 12:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1681–1704 of 2,347 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo Intravenous Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Tolerability of PRO 140 in HIV Uninfected Male Volunteers

NCT00110591
View directory record Official record
Conditions
HIV Infections
Interventions
PRO 140
Drug
Lead sponsor
CytoDyn, Inc.
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2008
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Mar 14, 2023 · Synced Oct 18, 2026, 12:29 AM EDT
Completed Phase 3 Interventional Results available

Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer

NCT01057810
View directory record Official record
Conditions
Prostate Cancer
Interventions
Ipilimumab, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older · Male only
Enrollment
837 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
42
States / cities
Anchorage, Alaska • Scottsdale, Arizona • Tucson, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2016 · Synced Oct 18, 2026, 12:29 AM EDT
Terminated Phase 1 Interventional

Phase Ib/II Study of M3814 With Etoposide and Cisplatin in Small Cell Lung Cancer (SCLC) Extensive Disease (ED)

NCT03116971
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
M3814, Cisplatin, Etoposide
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
16
States / cities
Mesa, Arizona • Santa Rosa, California • Whittier, California + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2020 · Synced Oct 18, 2026, 12:29 AM EDT
Completed Phase 4 Interventional Results available

Effects of Intravenous Acetaminophen on Body Temperature and Hemodynamic Responses in Febrile Critically Ill Adults

NCT01869699
View directory record Official record
Conditions
Fever, Critical Illness
Interventions
Acetaminophen, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
2
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 9, 2017 · Synced Oct 18, 2026, 12:29 AM EDT
Withdrawn Early Phase 1 Interventional Accepts healthy volunteers

J-Tip® Jet Injection of 1% Buffered Lidocaine or Saline Versus 4% Lidocaine Cream Before Venipuncture or IV Insertion

NCT00924963
View directory record Official record
Conditions
Pain
Interventions
J-Tip jet injector, Jet injection saline, lidocaine cream
Device · Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
7 Years to 21 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Liberty Township, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 21, 2020 · Synced Oct 18, 2026, 12:29 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Intravenous Iron vs. Oral Iron Supplementation for Postpartum Anemia

NCT05047211
View directory record Official record
Conditions
Anemia, Iron Deficiency, Delivery Complication
Interventions
Ferrous sulfate, Iron dextran
Drug
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 29, 2023 · Synced Oct 18, 2026, 12:29 AM EDT
Terminated Phase 2 Interventional

Pharmacokinetics, Pharmacodynamics and Safety Evaluation of SAR279356 in Intensive Care Unit Mechanically Ventilated Patients

NCT01389700
View directory record Official record
Conditions
Infection Prophylaxis
Interventions
SAR279356, placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
6
States / cities
Los Angeles, California • Stanford, California • Jacksonville, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2014 · Synced Oct 18, 2026, 12:29 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis

NCT02407236
View directory record Official record
Conditions
Colitis, Ulcerative, Inflammatory Bowel Diseases
Interventions
Placebo IV, Placebo SC, Ustekinumab IV, Ustekinumab SC
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
961 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
68
States / cities
Birmingham, Alabama • La Mirada, California • Los Angeles, California + 65 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 18, 2026, 12:29 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy of Bevacizumab in Combination With Tarceva for Advanced Non-Small Cell Lung Cancer

NCT00130728
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
bevacizumab, erlotinib HCl, placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
636 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2019
U.S. locations
4
States / cities
Vallejo, California • Athens, Georgia • Kansas City, Kansas + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2021 · Synced Oct 18, 2026, 12:29 AM EDT
Withdrawn Phase 4 Interventional

Parenteral Ascorbic Acid Repletion in TransplantatIon

NCT04756063
View directory record Official record
Conditions
Liver Transplant Failure and Rejection
Interventions
Ascorbic acid, Placebo
Drug · Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 18, 2026, 12:29 AM EDT
Completed Phase 2Phase 3 Interventional

Prometa Pharmacotherapy for Methamphetamine Dependence

NCT00260481
View directory record Official record
Conditions
Drug Abuse, Drug Dependence
Interventions
Prometa, Placebo
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 22, 2016 · Synced Oct 18, 2026, 12:29 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of LY3016859 in Participants With Diabetic Nephropathy

NCT01774981
View directory record Official record
Conditions
Diabetic Nephropathy
Interventions
Placebo, LY3016859
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
6
States / cities
Clearwater, Florida • Omaha, Nebraska • Bethlehem, Pennsylvania + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2019 · Synced Oct 18, 2026, 12:29 AM EDT
Terminated Phase 2 Interventional

A Phase 2 Study of VLX-1005 Versus Placebo in Suspected Heparin Induced Thrombocytopenia

NCT05785819
View directory record Official record
Conditions
Thrombocytopenia, Immune, Heparin Induced Thrombocytopenia
Interventions
VLX-1005, Placebo
Drug
Lead sponsor
Veralox Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
14
States / cities
Stanford, California • Aurora, Colorado • New Haven, Connecticut + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced Oct 18, 2026, 12:29 AM EDT
Completed Phase 2Phase 3 Interventional

Safety and Efficacy Study of SYN115 in Parkinson's Patients Using Levodopa to Treat End of Dose Wearing Off

NCT01283594
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Tozadenant (SYN115) 60 mg BID, Placebo, Levodopa (L-dopa), Tozadenant (SYN115) 120 mg BID, Tozadenant (SYN115) 180 mg BID, Tozadenant (SYN115) 240 mg BID
Drug
Lead sponsor
Biotie Therapies Inc.
Industry
Eligibility
30 Years to 80 Years
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
40
States / cities
Birmingham, Alabama • La Jolla, California • Loma Linda, California + 37 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2019 · Synced Oct 18, 2026, 12:29 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety and Pharmacokinetics of a Single Intravenous Administration of CNTO 328 Derived From 2 Different Cell Lines in Healthy Participants

NCT02074800
View directory record Official record
Conditions
Healthy
Interventions
CNTO 328 (Sp2/0-derived), CNTO 328 (CHO-derived), Placebo
Drug
Lead sponsor
Centocor, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
145 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
2
States / cities
Lincoln, Nebraska • Neptune City, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 5, 2015 · Synced Oct 18, 2026, 12:29 AM EDT
Completed Phase 1Phase 2 Interventional

Umbilical Cord Lining Stem Cells (ULSC) in Patients With COVID-19 ARDS

NCT04494386
View directory record Official record
Conditions
Covid19, Corona Virus Infection, SARS-CoV Infection, ARDS, Coronavirus
Interventions
Umbilical Cord Lining Stem Cells (ULSC), Placebo (carrier control)
Biological · Other
Lead sponsor
Restem, LLC.
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
2
States / cities
Miami, Florida • Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Apr 9, 2024 · Synced Oct 18, 2026, 12:29 AM EDT
Completed Phase 2 Interventional Results available

Dose/ Schedule Finding Trial of Romiplostim for Chemotherapy-Induced Thrombocytopenia (CIT) in Non-Small Cell Lung Cancer (NSCLC)

NCT00413283
View directory record Official record
Conditions
Lung Cancer, Chemotherapy-Induced Thrombocytopenia, Non-Small Cell Lung Cancer, Cancer, Lung Neoplasms, Oncology, Solid Tumors, Thrombocytopenia
Interventions
Romiplostim, Placebo, Gemcitabine, Carboplatin, Cisplatin
Biological · Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
51
States / cities
Glendale, Arizona • Anaheim, California • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2013 · Synced Oct 18, 2026, 12:29 AM EDT
Completed Phase 3 Interventional

Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)

NCT03924856
View directory record Official record
Conditions
Bladder Cancer
Interventions
Pembrolizumab, Gemcitabine, Cisplatin, Surgery (radical cystectomy (RC) plus Pelvic Lymph Node Dissection [PLND]), Placebo
Drug · Procedure
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
907 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
24
States / cities
La Jolla, California • Santa Monica, California • Washington D.C., District of Columbia + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 18, 2026, 12:29 AM EDT
Completed Phase 3 Interventional

A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis (UC)

NCT04630028
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
Ustekinumab Dose Based on BSA and Body Weight, Matching Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
2 Years to 17 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
9
States / cities
Wilmington, Delaware • Atlanta, Georgia • Rochester, Minnesota + 6 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 18, 2026, 12:29 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluation of Kisspeptin Glucose-Stimulated Insulin Secretion With Oral Glucose Tolerance Test

NCT04958109
View directory record Official record
Conditions
Metabolic Diseases
Interventions
Oral Glucose Tolerance Test, Kisspeptin, Placebo
Diagnostic Test · Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 6, 2026 · Synced Oct 18, 2026, 12:29 AM EDT
Terminated Phase 2 Interventional Results available

Study of ARC-520 in Participants With Hepatitis B Virus e Antigen (HBeAg) Positive Chronic Hepatitis B Virus

NCT02452528
View directory record Official record
Conditions
Chronic Hepatitis B
Interventions
ARC-520, Placebo, Entecavir, Tenofovir, diphenhydramine
Drug
Lead sponsor
Arrowhead Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
4
States / cities
San Francisco, California • Miami, Florida • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2025 · Synced Oct 18, 2026, 12:29 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of a Single Ascending Dose Study of DS-7011a in Healthy Subjects

NCT05203692
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
DS-7011a, Placebo
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 45 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
2
States / cities
Long Beach, California • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 11, 2023 · Synced Oct 18, 2026, 12:29 AM EDT
Completed Phase 2 Interventional Results available

A Multiple Dose Study of PF-04950615 (RN316) in Subjects on High Doses of Statins

NCT01342211
View directory record Official record
Conditions
Hypercholesterolemia, Dyslipidemia
Interventions
Placebo, Statin, PF-04950615 (RN316), Satin
Biological · Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
38
States / cities
Tustin, California • Walnut Creek, California • Clearwater, Florida + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2017 · Synced Oct 18, 2026, 12:29 AM EDT
Completed Phase 3 Interventional Results available

A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-03)

NCT02943577
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Rapastinel, Placebo
Drug
Lead sponsor
Naurex, Inc, an affiliate of Allergan plc
Industry
Eligibility
18 Years to 65 Years
Enrollment
429 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
40
States / cities
Dothan, Alabama • Phoenix, Arizona • Imperial, California + 34 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2019 · Synced Oct 18, 2026, 12:29 AM EDT